{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import glob"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_df(path, encoding=\"utf-8\"):\n",
    "    loaded_pd = pd.read_csv(path, sep=\"\\t\", encoding=encoding)\n",
    "    pd_name = path.split(\"/\")[-1].split(\".\")[0]\n",
    "    return pd_name, loaded_pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "paths_expression = glob.glob(\"data/expression data/*.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "expression_data = []\n",
    "for path in paths_expression:\n",
    "    expression_data.append(load_df(path))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "paths_other = glob.glob(\"data/*.txt\")\n",
    "aligner_path = \"data/phenotypes_id_aligner.txt\"\n",
    "other_data = []\n",
    "for path in paths_other:\n",
    "    if path == aligner_path:\n",
    "        other_data.append(load_df(path, encoding=\"latin\"))\n",
    "    else:\n",
    "        other_data.append(load_df(path))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## We have loaded the dataframes to lists\n",
    "\n",
    "Each list contains tuples (name, dataframe)\n",
    "- expression_data: tables with gene expressions\n",
    "- other_data: all the remaining tables\n",
    "\n",
    "### Predicting immune response\n",
    "\n",
    "We decide to use the \n",
    "The gene expression is the best indicator of the phenotype, so we check if there is missing data on expression that is of interest to us."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Muscle_CD'"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "expression_data[0][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "pheno_ids_df = pd.read_pickle(\"processed_data/PhenoID_Disease.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Shown_pheno</th>\n",
       "      <th>Disease</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>PhenoID</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>X657</td>\n",
       "      <td>H5N1 influenza A virus mortality rate 30 days ...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X893</td>\n",
       "      <td>H5N1 influenza A virus survival time (10^4 EID...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X3655</td>\n",
       "      <td>Malaria infection lethality, Plasmodium yoelii...</td>\n",
       "      <td>Malaria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X4233</td>\n",
       "      <td>Malaria susceptibility, murine Plasmodium yoel...</td>\n",
       "      <td>Malaria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X593</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1868</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X2558</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X544</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1481</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X2637</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X2468</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1071</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), per...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1832</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1618</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), per...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1586</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X511</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), per...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X217</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), per...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1797</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), per...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X419</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), mea...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X2030</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1288</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X1573</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X2275</td>\n",
       "      <td>H1N1 (PR8) influenza A virus (2x10E3 FFU), med...</td>\n",
       "      <td>Influenza</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X670</td>\n",
       "      <td>Malaria lethality, Plasmodium yoelii (PY17X su...</td>\n",
       "      <td>Malaria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>X3733</td>\n",
       "      <td>Malaria lethality, Plasmodium yoelii (PY17X su...</td>\n",
       "      <td>Malaria</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               Shown_pheno    Disease\n",
       "PhenoID                                                              \n",
       "X657     H5N1 influenza A virus mortality rate 30 days ...  Influenza\n",
       "X893     H5N1 influenza A virus survival time (10^4 EID...  Influenza\n",
       "X3655    Malaria infection lethality, Plasmodium yoelii...    Malaria\n",
       "X4233    Malaria susceptibility, murine Plasmodium yoel...    Malaria\n",
       "X593     H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X1868    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X2558    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X544     H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X1481    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X2637    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X2468    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X1071    H1N1 (PR8) influenza A virus (2x10E3 FFU), per...  Influenza\n",
       "X1832    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X1618    H1N1 (PR8) influenza A virus (2x10E3 FFU), per...  Influenza\n",
       "X1586    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X511     H1N1 (PR8) influenza A virus (2x10E3 FFU), per...  Influenza\n",
       "X217     H1N1 (PR8) influenza A virus (2x10E3 FFU), per...  Influenza\n",
       "X1797    H1N1 (PR8) influenza A virus (2x10E3 FFU), per...  Influenza\n",
       "X419     H1N1 (PR8) influenza A virus (2x10E3 FFU), mea...  Influenza\n",
       "X2030    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X1288    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X1573    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X2275    H1N1 (PR8) influenza A virus (2x10E3 FFU), med...  Influenza\n",
       "X670     Malaria lethality, Plasmodium yoelii (PY17X su...    Malaria\n",
       "X3733    Malaria lethality, Plasmodium yoelii (PY17X su...    Malaria"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pheno_ids_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "pheno_joined = other_data[1][1].set_index(\"PhenoID\")\n",
    "pheno_joined = pheno_joined.join(pheno_ids_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.to_pickle(pheno_joined[~pheno_joined[\"Disease\"].isna()], \"processed_data/pheno_joined_present.pkl\")\n",
    "pd.to_pickle(pheno_joined[pheno_joined[\"Disease\"].isna()], \"processed_data/pheno_joined_absent.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "pheno_ids = [\"X3873\"]\n",
    "strains = []\n",
    "for pheno_id in pheno_ids:\n",
    "    pheno_df = other_data[1][1][]\n",
    "    pheno_present = pheno_df[pheno_df.columns[~pheno_df.isnull().all()]].iloc[:,1:].transpose()\n",
    "    pheno_present.columns = [\"Expression\"]\n",
    "    pheno_absent = pheno_df[pheno_df.columns[pheno_df.isnull().all()]].transpose()\n",
    "    pheno_absent.columns = [\"Expression\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PhenoID</th>\n",
       "      <th>B6D2F1</th>\n",
       "      <th>D2B6F1</th>\n",
       "      <th>C57BL.6J</th>\n",
       "      <th>DBA.2J</th>\n",
       "      <th>BXD1</th>\n",
       "      <th>BXD2</th>\n",
       "      <th>BXD5</th>\n",
       "      <th>BXD6</th>\n",
       "      <th>BXD8</th>\n",
       "      <th>...</th>\n",
       "      <th>BXD90</th>\n",
       "      <th>BXD91</th>\n",
       "      <th>BXD93</th>\n",
       "      <th>BXD94</th>\n",
       "      <th>BXD95</th>\n",
       "      <th>BXD98</th>\n",
       "      <th>BXD99</th>\n",
       "      <th>BXD100</th>\n",
       "      <th>BXD101</th>\n",
       "      <th>BXD102</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>5089</td>\n",
       "      <td>X3873</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>100.22</td>\n",
       "      <td>158.28</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>76.12</td>\n",
       "      <td>NaN</td>\n",
       "      <td>111.26</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows × 98 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     PhenoID  B6D2F1  D2B6F1  C57BL.6J  DBA.2J  BXD1  BXD2  BXD5  BXD6  BXD8  \\\n",
       "5089   X3873     NaN     NaN    100.22  158.28   NaN   NaN   NaN   NaN   NaN   \n",
       "\n",
       "      ...  BXD90  BXD91  BXD93  BXD94  BXD95  BXD98  BXD99  BXD100  BXD101  \\\n",
       "5089  ...    NaN    NaN    NaN    NaN    NaN    NaN    NaN   76.12     NaN   \n",
       "\n",
       "      BXD102  \n",
       "5089  111.26  \n",
       "\n",
       "[1 rows x 98 columns]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "other_data[1][1][other_data[1][1][\"PhenoID\"] == \"X3873\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Expression</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>B6D2F1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>D2B6F1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD2</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD5</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD94</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD95</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD98</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD99</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>BXD101</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>84 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        Expression\n",
       "B6D2F1         NaN\n",
       "D2B6F1         NaN\n",
       "BXD1           NaN\n",
       "BXD2           NaN\n",
       "BXD5           NaN\n",
       "...            ...\n",
       "BXD94          NaN\n",
       "BXD95          NaN\n",
       "BXD98          NaN\n",
       "BXD99          NaN\n",
       "BXD101         NaN\n",
       "\n",
       "[84 rows x 1 columns]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pheno_absent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Muscle_CD',\n",
       " 'Cerebellum',\n",
       " 'Liver_HFD',\n",
       " 'Striatum',\n",
       " 'Liver_CD',\n",
       " 'VTA',\n",
       " 'Adrenal_Female',\n",
       " 'Hypothalamus_Female',\n",
       " 'Amygdala_Female',\n",
       " 'Liver_metabolite_HFD',\n",
       " 'Spleen_Male',\n",
       " 'Pituitary_Female',\n",
       " 'ScWAT_HFD',\n",
       " 'ScWAT_CD',\n",
       " 'Brain_INIA',\n",
       " 'PFC',\n",
       " 'Muscle_metabolite_HFD',\n",
       " 'Muscle_metabolite_CD',\n",
       " 'Heart_CD',\n",
       " 'Pituitary_Male',\n",
       " 'Hypothalamus_Male',\n",
       " 'Heart_HFD',\n",
       " 'Midbrain',\n",
       " 'BAT',\n",
       " 'Muscle_HFD',\n",
       " 'Nucleus_accumbens',\n",
       " 'Kidney_Female',\n",
       " 'Brain_UTHSC',\n",
       " 'Amygdala_Male',\n",
       " 'Adrenal_Male',\n",
       " 'Kidney_Male',\n",
       " 'Hippocampus',\n",
       " 'Bone_Femur',\n",
       " 'Gastrointestinal',\n",
       " 'LiverProt_CD',\n",
       " 'LiverProt_HFD',\n",
       " 'Spleen_Female',\n",
       " 'Liver_metabolite_CD',\n",
       " 'Lung',\n",
       " 'Eye']"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[name for name, table in expression_data]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['map_BXD', 'Phenotype', 'genotype_BXD', 'phenotypes_id_aligner']"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[name for name, table in other_data]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Infectious disease, immune system: H5N1 influenza A virus mortality rate 30 days after infection (10^4 EID-50 of HK213 virus in 30 microliters saline) [% death]',\n",
       " 'Infectious disease, immune system: H5N1 influenza A virus survival time (10^4 EID-50 of HK213 virus in 30 microliters saline) [days, max to 30]',\n",
       " 'Immune system: ELISA-3x, IgG class antibody binding to TSHR A-subunit protein in ELISA 4 weeks after 3 immunizations with TSHR A-subunit adenovirus [OD490 nm]',\n",
       " 'Immune system, endocrinology: serum inhibition of TSH binding to the TSHR before immunization [% inhibition] ',\n",
       " 'Immune system, endocrinology: Serum inhibition of TSH binding to the TSHR 4 weeks after 3 immunizations with TSHR A-subunit adenovirus in young adult females [% inhibition]',\n",
       " 'Immune system, endocrine system: TBI-2x, serum inhibition of TSH binding to the TSHR 1 week after 2 immunizations with TSHR A-subunit adenovirus [% inhibition]',\n",
       " 'Immune system: ELISA-2x, IgG class antibody binding to TSHR A-subunit protein in ELISA 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus [OD 490 nm]',\n",
       " 'Infectious disease, immune system: Malaria infection lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old males and females (0 = 100% resistant, 1 = 100% susceptible) [fraction of cohort that survives]',\n",
       " 'Infectious disease, immune system: Ectromelia virus mortality score (combined data from Brownstein 1999 and Rice et al. 2010) [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale]',\n",
       " 'Infectious disease, immune system: Malaria susceptibility, murine Plasmodium yoelli 17X-lethal (PY17X-L) [0=100% resistant, 1= 100% susceptible]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 5 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 4 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 8 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 6 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 7 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 2 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 3 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 9 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 1 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 10 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 10 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 8 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 7 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 11 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), mean time to death after infection in 9-14 week-old females [days]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 11 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 12 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 13 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 9 after infection in 9-14 week-old females [%]',\n",
       " 'Infectious disease, immune function: Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old females (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives]',\n",
       " 'Infectious disease, immune function: Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC) in 7-12 week-old males (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives]',\n",
       " 'Infectious disease, immune system: TNFa cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL]',\n",
       " 'Infectious disease, immune system: MCP1 cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL]',\n",
       " 'Infectious disease, immune system: Interferon alpha (IFNa) cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL]',\n",
       " 'Infectious disease, immune system: Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, ',\n",
       " 'Infectious disease, immune system: Ectromelia virus survival over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.33 days/unit]',\n",
       " 'Infectious disease, immune system: Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence of l',\n",
       " 'Infectious disease, immune function: Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old females (1=resistant and 0= susceptible)[survival fraction]',\n",
       " 'Infectious disease, immune system: Ectromelia virus measure of disease onset measured by the day of maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex,',\n",
       " 'Infectious disease, immune system: Malaria susceptibility, murine Plasmodium yoelli 17 (PY17X-L) [0=resistant, 1= susceptible]',\n",
       " 'Infectious disease, immune function: Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old males (1=resistant and 0= susceptible)[survival fraction]',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues, TAFI13',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI12',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI8',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI9',\n",
       " 'Infectious disease, immune system: Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence ',\n",
       " 'Infectious disease, immune system: Ectromelia virus euthanasia scale over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [-1 is survival, +2 is rapid ',\n",
       " 'Infectious disease, immune system: Ectromelia virus survival over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.7 days/unit]',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI10',\n",
       " 'Infectious disease, immune system: Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for s',\n",
       " 'Infectious disease, immune function: Ectromelia virus measure of disease onset, day of maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI11',\n",
       " 'Immune system, cardiovascular system: Peripheral blood lymphocytes, percentage of B cells [B220 %]',\n",
       " 'Immune system, cardiovascular system: Peripheral blood lymphocytes, percentage of CD8+ T cells [%]',\n",
       " 'Immune system, cardiovascular system: Peripheral blood lymphocytes, percentage of CD4+ T cells [%]',\n",
       " 'Infectious disease, immune system: Staphloccocus pyogenes (sq injection of 1.0x10x8 CFU) survival index in males and females injected at 10_¾_16 weeks of age (scored as follows: death before day 3 = 1, death from 3 to 7 = 2, death after day 7 =3) [index]',\n",
       " 'Immune system, cardiovascular system: Peripheral blood lymphocytes, CD4+/CD8+ T cell ratio, males at 3-5 month [ratio]',\n",
       " 'Infectious disease, immune function: Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males only between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions',\n",
       " 'Infectious disease, immune function: Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, females between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions wh',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI6',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI7',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 4 [%]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 3 [%]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 2 [%]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections survival after infection corrected for strain, sex, age and body weight given as corrected relative survival index [-1.5 = high',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 1 [%]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections lesion size after infection corrected for strain, sex, age and body weight given as maximum lesion area [Sq.mm]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight given as principal component 1 of day 1 to da',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI3',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, virulence following corneal infection, young adult male and female (combined) [percent mortality]',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 4 [% change in body weight]',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI1',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI5',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI4',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI2',\n",
       " 'Infectious disease, immune system: Cowpox virus survival over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [~2.67/unit]',\n",
       " 'Infectious disease, immune system: Immune response to bacterial LPS, polymorphonuclear macrophage after 4 hr acute, bronchial lavage [1000/ml]',\n",
       " 'Infectious disease, immune system, pulmonary system: Coccidioides immitis (Valley fever, San Joaquin California disease fungus, Coccidioidomycosis) susceptibility after an IP injection (500 - 800 CFU of the RS strain) in 7 to 12-week-old females, 10 per ',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 2 [% change in body weight]',\n",
       " 'Infectious disease, immune system: Cowpox virus severity of disease measured by the maximum clinical score over two weeks after a 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age, and body',\n",
       " 'Infectious disease, immune system: Cowpox virus measure of disease onset measured by the day of maximum clinical score over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age',\n",
       " 'Infectious disease, immune system: Cowpox virus maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [scaled deg C where -0.5 is >',\n",
       " 'Infectious disease, immune system: Cowpox virus measure of disease onset measured by the day of maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, a',\n",
       " 'Infectious disease, immune system: Cowpox virus maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight at time of inoculation [scaled % l',\n",
       " 'Infectious disease, immune system: Cowpox virus measure of disease onset measured by the day of maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age an',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 3 [% change in body weight]',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss, first principal component, days 1-4 [% change in body weight]',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 1 [% change in body weight]',\n",
       " 'Infectious disease, immune function: Chlamydia muridarum upper genital tract disease severity (endometrium, uterine horn) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe] ',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, day of death [days]',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, [1=resistant, 0=sensitive]',\n",
       " 'Infectious disease, immune function: Chlamydia muridarum upper genital tract disease severity (oviduct) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe disease] ',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes disease severity, corrected relative survival index (Fig 1A, residuals after correction for age, sex, body weight and log inoculum, with added strains BXD76 and BXD80) [-1 = high susceptible, +1 is',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB2 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI14',\n",
       " 'Infectious disease, immune system: Kramer RM, Lamkin T, and colleagues TAFI15',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB1 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NS gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM]',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NP gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM]',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM]',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral M gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM]',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral HA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM]',\n",
       " 'Immune system, pulmonary system: Tumor necrosis factor (TNF)-alpha level in lung after aerosolized lipopolysaccharide (LPS) exposure [pg/ml]',\n",
       " 'Infectious disease, immune function: Cowpox virus disease onset measured by day of max clinical score over three weeks after 10^5pfu intranasal infection, males and females between XX and XXX days of age, residuals corrected for age, sex and body weight [',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, percent weight loss following corneal infection, young adult female and male [max weight loss %]',\n",
       " 'Immune system, pulmonary system: Polymorphonuclear leukocyte number (PMN) after aerosolized LPS exposure [PMN/ml (x103)]',\n",
       " 'Immune function: CD62L+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: Ly6C+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD44+ cells excluding CD62L cells as a percentage of CD8+ CD3+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: IgD+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: Gr-1-NKp46- CD11b+ as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD3+CD8a+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD3+ gamma/delta TCR+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: GR-1+ CD11b+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD62L+ cells excluding CD44 cells as a percentage of CD3+CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD44+ Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD62L+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD3+CD4+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD44+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD3+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD44+ effector-memory T cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (this trait maps to CD44 locus) (FACS) [%]',\n",
       " 'Immune function:CD5+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD44+ cells as a percentage of CD3+ CD4+ without CD62L cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD62L+ T cells without CD44 cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: B cells as a percentage of MHC class II (I/A-E) cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: CD25+ cells as a percentage of CD3+ CD4+ in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Infectious disease, immune system: Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units]deltaD2-D1_colo_Russo',\n",
       " 'Infectious disease, immune system: Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units] 3_colo_Russo ',\n",
       " 'Immune system, hematology: CD11b+ NKp46+ cells as a percentage of CD5-cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: B cells (CD19 or B220 and IgD) as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune function: Nkp46+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%]',\n",
       " 'Immune system, metabolism: Iron level in spleen of males [ug/g]',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (126b) infection response (50 CFU intranasal), survival in males, [1=resistant, 0=sensitive]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, percent weight loss following corneal infection, young adult male [max weight loss %]',\n",
       " 'Immune system, metabolism: Iron level in spleen of males and females [ug/g]',\n",
       " 'Immune system, aging: Hematopoietic stem cell and progenitor cell number (lin-Sca1++ c-kit+ cells) from femur bone marrow of females a 18 months (confirm) (unpublished additional data) [n cells]',\n",
       " 'Immune system, metabolism: Iron level in spleen of females [ug/g] ',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection) sepsis bacteremia 24 h post-infection corrected for age, sex, body weight, log inoculum (Fig 1B) [corrected log CFU/ml]',\n",
       " 'Immune system, aging: Progenitor cell proliferation in young mice (2 months of age), effect of TGFB2 (0.1 ng/ml) on the proliferation of lin-Sca1++kit+ cells relative to control without TGFB2 [%]',\n",
       " 'Infectious disease, immune system: Bronchoalveolar lavage (BAL) lung lymphocyte cell number following infection with Acinetobacter baumannii [units/ul]',\n",
       " 'Immune system, aging: Percentage of hematopoietic stem cells and progenitor cells in femur bone marrow (lin-Sca1++ c-kit+) at 18 months of age (Figure 2B of paper) [%]',\n",
       " 'Immune system, aging: Percentage of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow [%]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, percent maximum weight loss following corneal infection, young adult female (combined) [max weight loss %]',\n",
       " 'Immune system, aging: Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (Fig 2A of paper) [n per well]',\n",
       " 'Infectious disease, immune system: Acinetobacter baumannii infection, bronchoalveolar lavage (BAL) lung lymphocyte cell number following (BXD65 winsorized from 47.5 to 26.0) [units/ul]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, stromal keratitis severity following corneal infection, young adult male and female (combined) [ordinal 1 t0 5 scale, 0=none, 5 = penetrating lesions]',\n",
       " 'Immune system, hematopoesis, aging: Hematopoietic stem cells and progenitor cells, numbers of Lin-Sca1++ cells at 2 months of age in females (Figure 3B of paper) [n]',\n",
       " 'Immune system, hematopoesis, aging: Hematopoietic stem cell and progenitor cell proliferative capacity (Lin-Sca1++ cells from femur bone marrow), in vitro assay of cells from 2-3 month old females in response to KL, flt3L, and TPO (Figure 3A of paper) [n ',\n",
       " 'Infectious disease, immune system: Sendai virus lethality with 1.0 TCID50 [% mortality]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes disease severity, corrected relative survival index (differs from Fig 1A slightly, residuals after correction for age, sex, body weight and log inoculum, with added strain BXD80) where -1 means hig',\n",
       " 'Infectious disease, immune system: Ectromelia virus-induced mortality [3 = resistant, 1 = both intermediate and susceptible, ordinal scale]',\n",
       " 'Infectious disease, immune system: Streptococcus pyogenes (Group A streptococcal infection) dissemination to spleens, 24 h post-infection (Fig 1C) [CFU/ml]',\n",
       " 'Immune system, gastrointestinal system: Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 positive T cells) [%]',\n",
       " 'Immune system, gastrointestinal system: Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 negative T cells) from Fig 4 x-axis [%]',\n",
       " 'Immune system, aging: Stem cell frequency, cobblestone area-forming cell assay count (CAFC) on day 35 [CAFC per 10e5 bone marrow cells]',\n",
       " 'Immune system, aging: Proliferative activity of hematopoietic stem cells on day 7 in culture [% CAFC]',\n",
       " 'Immune system, aging: Hematopoietic stem cell number (cobblestone-area-forming cells per femur at 35 days of age from 3 females, also previously published) [n]',\n",
       " 'Immune system, hematopoesis, aging: Relative fraction of hematopoietic stem cells and progenitor cells (Lin-Sca1++) from bone marrow in 2-3 month old females (Figure 3C of paper) [%]',\n",
       " 'Infectious disease, immune system: Myoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection gross pulmonary lesions [burden]',\n",
       " 'Immune system, gastrointestinal system: Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 negative T cells) from Fig 4 y-axis [%]',\n",
       " 'Immune system, gastrointestinal system: Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 positive T cells) [%]',\n",
       " 'Infectious disease, immune system: Ectromelia virus-induced mortality in males [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale]',\n",
       " 'Immune system, aging: Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (additional data not included in paper) [n cells total]',\n",
       " 'Infectious disease, immune system: Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU), fraction dead 21 days after infection [ratio]',\n",
       " 'Immune system: TRBV4+ T cell levels among CD8+ T cells in spleen [%]',\n",
       " 'Infectious disease, immune system: Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway lymphoid hyperplasia',\n",
       " 'Infectious disease, immune system: Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway exudate [units]',\n",
       " 'Infectious disease, immune system, pulmonary system: Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway epithelial hyperplasia',\n",
       " 'Infectious disease, immune system: EOMES coefficient (Malak Kotb and colleagues 2014) Please provide a full description of the trait now here with information on sex, age range, innoculum, route of infection etc. [units]',\n",
       " 'Infectious disease, immune function: Please enter the full trait description here even BEFORE publication. Only you will see these descriptions.',\n",
       " 'Infectious disease, immune system: Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, alveolar exudate [units]',\n",
       " 'Immune system, infectious disease: Rickettsiu tsutsugamushi susceptibility (strain Gilliam, ip 100 50% mouse infectious doses, two treatments) of both sexes at 6-12 weeks-of-age (ordinal scale 0 = resistant, 1=susceptible, also see BXH RI set), maps to Gb',\n",
       " 'Immune system: TRBV4+ T cell levels among CD8+ T cells in peripheral blood [%]',\n",
       " 'Infectious disease, immune function: Susceptibility to Staphylococcus aureus, colony forming units (CFU) in heart 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)]',\n",
       " 'Immune system: Tumor necrosis factor (TNF) lethality after injection [%]',\n",
       " 'Infectious disease, immune system: Chlamydia psittaci (6BC) infection response (10^4 IFU ip), survival index at 11 days in 2-4 month males [mean score, 0=resistant, 1=weight loss and all survive, 2=weight loss some survive, 3=no survival]',\n",
       " 'Immune system: Proliferation of T cell clone (JTL-G12.8 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm]',\n",
       " 'Immune system: Proliferation of T cell clone (JTL-G12.8 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm]',\n",
       " 'Immune system: Proliferation of T cell clone (JTL-G12 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm]',\n",
       " 'Immune system: Proliferation of T cell clone (JTL-G12 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm]',\n",
       " 'Infectious disease, immune system, liver: Susceptibility to Staphylococcus aureus, colony forming units (CFU) in liver 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)]',\n",
       " 'Infectious disease, immune system, urogenital system, kidney: Susceptibility to Staphylococcus aureus, colony forming units (CFU) in kidney 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)]',\n",
       " 'Infectious disease, immune function: Susceptibility to Staphylococcus aureus, colony forming units (CFU) in blood 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)]',\n",
       " 'Immune system, aging: Proliferative capacity in vitro of bone marrow stem and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age in response to KL, flt3L and TPO (figure 2C of paper) [n cells]',\n",
       " 'Immune system: Thymic T-cell proliferative unresponsiveness (anergy) to anti-CD3-induced proliferation (chemokine-associated) [units]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) footpad swelling, 3 weeks post infection in females (BXD80 winsorized from 196 to 120) [% of C57BL/6 control]',\n",
       " 'Immune system: lymphocyte major glycoprotein (gp70) xenotropic leukemia virus envelope-related cell-surface antigen (XenCSA) level measured as mean fluorescence value (sum of products of each channel number times the number of spleen cells in that channel',\n",
       " 'Lung, immune system: Airway bronchial constrictor response after exposure to atracurium, airway pressure time index [cmH2O/s]',\n",
       " 'Infectious disease, immune system: Log Day 1 of counts of E coli colonization in BXD strains colon after infection with 109 cfu of E. coli strain O157:H7, isolate Tuv 86-2 (Stx2-), intra-gastric gavage, female mice, 5_¾_7 weeks old [CFU/g feces]',\n",
       " 'Infectious disease, immune system: xenotropic MuLV envelope-related cell-surface antigens (XenCSA) levels on thymus cells measured as mean fluorescence value (sum of products of each channel number times n cells in that channel divided by n cells counted)',\n",
       " 'Infectious disease, immune function: Susceptibility to Staphylococcus aureus, mean time of death in days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [days]',\n",
       " 'Infectious disease, immune function: Susceptibility to Staphylococcus aureus, % survival after 4 days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [%]',\n",
       " 'Infectious disease, immune function: Susceptibility to Staphylococcus aureus, survival 10 days after infection with 10E5 colony forming units (CFU) in 10 to 14 day-old females [%]',\n",
       " 'Immune system, morphology, nutrition: Spleen weight of 120-day-old males and females fed 3 ppm Fe diet [g]',\n",
       " 'Immune system: Phenyloxazolone hapten-induced Igh-Ox antibody marker level (public idiotype)[units]',\n",
       " 'Immune system, development: Hematopoietic stem cell pool size, cobblestone area-forming cells per 100,000 bone marrow cells [n]',\n",
       " 'Immune system: Granulocyte colony stimulating factor (G-CSF) induced progenitor cell mobilization from bone marrow to blood [PB-CFC/ul]',\n",
       " 'Immune system, morphology, nutrition: Iron level in spleen of 120-day-old females fed 3 ppm Fe diet [ug/g]',\n",
       " 'Immune system, metabolism, nutrition: Iron level in spleen of 120 day old males and females fed 3 ppm Fe diet [ug/g]',\n",
       " 'Immune system: V beta 3+ T cells in lymph nodes [%]',\n",
       " 'Infectious disease, immune system: Murine cytomegalovirus (MCMV) titer in spleen 4 days after infection with 5X10^4 PFU (KLRA complex) [log10 burden]',\n",
       " 'Immune system, morphology, nutrition: Spleen weight of 120-day-old females fed 3 ppm Fe diet [g]',\n",
       " \"Toxicology, cancer biology: Skin tumors after initiation with N-methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [n per case]\",\n",
       " 'Immune system, morphology, nutrition: Iron level in spleen of 120-day-old females fed 270 ppm Fe diet [ug/g]',\n",
       " 'Immune system, morphology, nutrition: Spleen weight of 120-day-old males fed 3 ppm Fe diet [g]',\n",
       " 'Immune system, morphology, nutrition: Spleen weight of 120-day-old males and females fed 270 ppm Fe diet [g]',\n",
       " 'Immune system, metabolism, nutrition: Iron level in spleen of 120 day old males and females fed 270 ppm Fe diet [ug/g]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), parasite burden in feet 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Cancer biology, liver, toxicology: Hepatocellular carcinoma tumor multiplicity in liver of males after infection with 0.01 ml/g body wt N,N-diethylnitrosamine [n]',\n",
       " \"Toxicology, cancer biology: Skin tumor incidence following initiation with N-Methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [% mice]\",\n",
       " 'Immune system, morphology, nutrition: Spleen weight of 120-day-old females fed 270 ppm iron (Fe) diet [g]',\n",
       " 'Immune system, metabolism, nutrition: Iron level in spleen of 120 day old males fed 3 ppm Fe diet [ug/g]',\n",
       " 'Cancer biology, liver, toxicology: Hepatocellular carcinoma tumor multiplicities induced by N,N-diethylnitrosamine (DEN 0.01 ml/g, ip at postnatal day 12), mean tumor multiplicity in liver at 32 weeks in male [n]',\n",
       " 'Immune system, morphology: Spleen weight, splenomegaly induced by Bacillus Calmette_¾_Gu\\x90©rin tuberculosis vaccine (iv injection in oil and saline) (BCG) [mg]',\n",
       " 'Infectious disease, immune system, pulmonary system: Lung inflammatory response, pulmonary granulomatous inflammation induced by Bacillus Calmette_¾_Gu\\x90©rin tuberculosis vaccine (BCG) [units]',\n",
       " 'Infectious disease, immune system, protein: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), tumor necrosis factor alpha level (TNFA, Chr 17 at 35 Mb) from draining lymph node 3 weeks post infection in females using Luminex assay ',\n",
       " 'Infectious disease, immune system: Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as tumor necrosis factor alpha (TNFa) cytokine expression [pg/ml]',\n",
       " 'Infectious disease, immune system: Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interferon gamma (IFNG) cytokine expression [ng/ml/]',\n",
       " 'Infectious disease, immune system: Anergy measured by footpad thickness resulting from BCG injection [mm]',\n",
       " \"Infectious disease, immune system: Theiler's murine encephalomyelitis virus (TMEV) spinal cored demyelination susceptibility (excludes strains with B allele at H2 locus) [% affected]\",\n",
       " 'Immune system: Tumor necrosis factor (TNF) lethal shock, induction of serum interleukin 6 (IL-6) cytokine after injection [ng/ml]',\n",
       " 'Immune system, metabolism: Tumor necrosis factor (TNF)-induced hypothermia [degree C]',\n",
       " 'Immune system, aging: Proliferative capacity, number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2, 0.01 ng/ml) at 18 months of age (confirm) (unpublished additiona',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, spleen weight following corneal infection, young adult male and female (combined) [g]',\n",
       " 'Infectious disease, immune system: Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interleukin 6 (IL-6) cytokine expression [pg/ml]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), vascular endothelial growth factor (VEGF) level from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Immune system, morphology, nutrition: Spleen weight of 120-day-old males fed 270 ppm Fe diet [g]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-3 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-5 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-6 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Immune system, metabolism, nutrition: Iron level in spleen of 120 day old males fed 270 ppm Fe diet [ug/g]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-13 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-17 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) IP-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), chemokine (C-X-C motif) ligand 1 level (CXCL1, KC, Chr 5 at 91 Mb) from draining lymph node 3 weeks post infection in females [% of C57BL/6 contro',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) LIF from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), monocyte chemoattractant protein-1 (MCP1) level from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), macrophage inflammatory protein-1 beta (MIP1B) from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) MIG alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) RANTES from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-4 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune function: Leishmania major (footpad injection of 5 million promastigotes at 7 weeks) granulocyte macrophage colony-stimulating factor (GM-CSF) level from draining lymph node, 3 weeks after infection in females (Luminex assay) [%',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) Interferon-gamma from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), interleukin-1 beta level (IL1B, Chr 2 at 129 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control]',\n",
       " 'Infectious disease, immune system: Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), granulocyte colony-stimulating factor (G-CSF, CSF3, Chr 11 at 98.6 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 con',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, anti-DNA antibodies sera titers, 13 month females (Fig 7 from Mountz et al., 2005) [natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4, ln of 0',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, spleen weight following corneal infection, young adult male [g]',\n",
       " 'Infectious disease, immune function: Linear bacterial load in liver 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / liver / 10]',\n",
       " 'Infectious disease, immune function: Lung weight/body weight 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [lung weight/body weight * 10000]',\n",
       " 'Infectious disease, immune function, pulmonary system: Bacterial load in lungs 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [log10 CFU / lung * 100]',\n",
       " 'Immune system, aging: Proliferative capacity, effect of TGF-beta2 stimulation (0.1 ng/ml) on numbers of lin-Sca1++ c-kit+ cells (unpublished additional data) [% increase]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of generalized autoimmunity measured as ratio of Ig to rheumatoid factor (RF) in 13-month-old mice [ratio, natural log of total Ig to RF (ELISA OD 450 x 10^4)]',\n",
       " 'Immune system, aging: Proliferative activity of hematopoietic stem cells, day 21 cobblestone area forming cell (CAFC) frequency change [% CAFC]',\n",
       " 'Immune system, aging: Proliferative activity of hematopoietic stem cells, change in quiescent HSC percentage (cobblestone area-forming cells day 35 of culture) at 20 months [% CAFC]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgM-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Immune system, aging: Stem cell cycling, change in day 7 cobblestone area forming cell (CAFC) frequency during aging [%CAFC]',\n",
       " 'Immune system, aging: Proliferative activity of hematopoietic stem cells, quiescent HSCs in aged mice, cobblestone area forming cells (CAFC) on day 35, frequency in bone marrow [CAFC per 10e5 bone marrow cells]',\n",
       " 'Immune system, aging: Proliferative activity of hematopoietic stem cells, quiescent stem cells in aged mice, cobblestone area forming cells (CAFC) at day 35 in culture, frequency in bone marrow [CAFC per 10e5 bone marrow cells]',\n",
       " 'Infectious disease, immune function: Linear bacterial load in spleen 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / spleen / 100]',\n",
       " 'Infectious disease, immune system: LacZ expression 21 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4]',\n",
       " 'Infectious disease, immune system, pulmonary system: Mycobacterium tuberculosis (H37Rv, 100 colony forming units (CFU)) response, bacterial load in lung 21 days after aerosol infection in 12-23 week-old females [linear CFU/lung/1000]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgG2b-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, rheumatoid factor sera titers, 13 month females (natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4)',\n",
       " 'Infectious disease, immune system: Cytotoxicity in spleen T cells 50 days post 5x109 PFU AdLacZ i.v injection [%]',\n",
       " 'Infectious disease, immune system: Cytotoxicity in spleen T cells 30 days post 5x109 PFU AdLacZ i.v injection [%]',\n",
       " 'Infectious disease, immune system: Cytotoxicity in spleen T cells 21 days post 5x109 PFU AdLacZ i.v injection [%]',\n",
       " 'Infectious disease, immune system: Cytotoxicity in spleen T cells 7 days after 5x109 PFU AdLacZ i.v injection [%]',\n",
       " 'Infectious disease, immune system: LacZ expression 50 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4]',\n",
       " 'Infectious disease, immune system: LacZ expression 30 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgG2a-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgG2b-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: LacZ expression 7 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of IgM-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgG1-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgG2a-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: Chlamydia psittaci (6BC) infection response (10^4 IFU ip), weight loss ratio at 11 days compared to baseline in 2-4 month males [ratio]',\n",
       " 'Infectious disease, immune system: Tuberculosis, bacterial load in lung (BXD71 winsorized from 4.18 to 4.98) [log CFU]',\n",
       " 'Immune system, morphology, aging: Thymus involution, age-related rate of decline measured as involution slope (-beta 1x10^4)',\n",
       " 'Immune system, morphology, aging: Thymocyte count in young adult mice, initial [Beta 0]',\n",
       " 'Immune system, morphology, aging: Thymocyte count, projected at 60 days [units]',\n",
       " 'Infectious disease, immune function: H1N1 (PR8) influenza A virus (2x10E3 FFU), body weight loss day 3 after infection in 9-14 week-old females [%] - individual mice from RNAseq experiment (HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM)',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of generalized Ig to anti-DNA in 13-month-old mice [natural log of total Ig to anti-DNA (ELISA OD 450 x 10^4)]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, spleen weight following corneal infection, young adult female [g]',\n",
       " 'Infectious disease, immune system, pulmonary system: Tuberculosis, bacterial load in lung [CFU]',\n",
       " 'Infectious disease, immune system: Salmonella typhimurium bacterial strain LT2-Z growth from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3, filled circles) [log10 CFU]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, serum neutralizing antibody titer in young adult females [unit]',\n",
       " 'Infectious disease, immune function: Linear bacterial load in spleen 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / spleen / 1000]',\n",
       " 'Immune system, morphology: Thymus to body size ratio [x10^3]',\n",
       " 'Infectious disease, immune system: Autoimmune disease, spontaneous development of immune response, IgG1-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)]',\n",
       " 'Infectious disease, immune system: IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, day 0 baseline [ELISA OD 450]',\n",
       " 'Immune system: IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 14 [ELISA OD 450]',\n",
       " 'Infectious disease, immune system: IgG2b anti-AAV2 (adeno-associated virus type 2) immune response following injection of 3xE11 vector genomes vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, on day 42 [ELISA OD 450]',\n",
       " 'Infectious disease, immune system: IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 120 [ELISA OD 450]',\n",
       " 'Infectious disease, immune system: Salmonella typhimurium bacterial strain WB500 from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3 open circles) [log10 CFU]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, serum neutralization titer following corneal infection, young adult male and female (combined) [unit]',\n",
       " 'Infectious disease, immune function: Linear bacterial load in lung 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / lung / 10000]',\n",
       " 'Infectious disease, immune system: IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3xE11 vector genomes (vg) /mouse AAV2-(ApoE)4/hAAT-cF.IX on day 180 [ELISA OD 450]',\n",
       " 'Infectious disease, immune function: Linear bacterial load in liver 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / liver / 100]',\n",
       " 'Infectious disease, immune function: Quantity of lung pathology 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [quantitative score (10 lowest - 70 highest)]',\n",
       " 'Infectious disease, immune function: Quantity of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [quantitative score (10 lowest - 70 highest)]',\n",
       " 'Infectious disease, immune function: Lung weight/body weight 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [lung weight/body weight * 10000]',\n",
       " 'Infectious disease, immune function: Bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [log10 CFU / lung * 100]',\n",
       " 'Infectious disease, immune function: Normalized bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ratio CFU BXD / CFU C57BL/6J * 100]',\n",
       " 'Infectious disease, immune function: Quality of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ordinal scale (10 = normal, 20 = intermediate, 30 = severe)]',\n",
       " 'Immune system, aging: Proliferative capacity change, difference between old (18 months) and young (2 months) on number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2',\n",
       " 'Infectious disease, immune system: Chlamydia psittaci (6BC) infection response (10^4 IFU ip), pathogen load in peritoneal cavity at 30 days among surviving 3-5 month males (subset of cases) [log ng of DNA] ',\n",
       " 'Infectious disease, immune system: Herpes simplex virus type 1, serum neutralizing antibody titer in young adult males [unit]',\n",
       " 'Infectious disease, immune system: Salmonella typhimurium bacterial strain SR-11, net growth in livers and spleens 6 days after inoculation with 10^2 CFU (figure 5, triangles, Itk/Nramp1/Slc11a1-associated) [log10 CFU]',\n",
       " 'Immune system, environmental toxicology: Airway inflammatory response to ozone (2 ppm for 3 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after acute exposure [number of PMNs x10^3]',\n",
       " 'Immune system, pulmonary system, environmental toxicology: Airway inflammatory response to ozone (0.30 ppm for 48 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after exposure [n PMNs x10^3]',\n",
       " 'Immune system, urogenital system, kidney: Immune complex deposits in kidney immunized with the 16/6 Id [0=no immune complexes; 1=1-5 immune complex deposits; 2=5-20 immune complex deposits; 3=20-50 immune complex deposits; 4=50 immune complex deposits]',\n",
       " 'Immune system, hematopoesis, aging: Hematopoietic stem cells and progenitor cells in femur bone marrow, percentage of c-kit-postiive cells to c-kit-ngative cells among Lin-Sca1++ cells in 2-month old femaies (Figure 3d of paper) [%]',\n",
       " 'Infectious disease, immune system: IgG1 isotype-specific anti-cF.IX (coagulation Factor IX) response following injection of 3e11 vg/mouse AAV2-cF.IX [ELISA OD 450 (x 10^4)]',\n",
       " 'Immune function: Antibody IgG1 response following iv injection of canine coagulation factor IX (cF.IX, 3E11 vg/mouse) [ng/ml]',\n",
       " 'Infectious disease, immune system, morphology: Chlamydia psittaci (6BC) infection response (10^4 IFU ip), spleen weight at 30 days among surviving animals, 2-4 months males (subset of cases from Miyiari 2007) [gm]',\n",
       " \"Infectious disease, immune system: Theiler's murine encephalomyelitis virus (TMEV, dermal injection), delayed-type hypersensitivity (DTH) response measured as ear swelling [inch x 1E-3]\",\n",
       " 'Cancer biology: Growth of syngeneic breast cancer tumors day 25 [mm3]',\n",
       " 'Cancer biology: Necrosis of implanted breast tumor [n]',\n",
       " 'Cancer biology: Syngeneic breast tumor growth, number of cases with tumor metastasis [n]',\n",
       " 'Cancer biology: Syngeneic breast cancer tumor growth, day 5 [mm3]',\n",
       " 'Cancer biology: Growth of syngeneic breast cancer tumors day 10 [mm3]',\n",
       " 'Cancer biology: Growth of syngeneic breast cancer tumors day 15 [mm3]',\n",
       " 'Cancer biology: Syngeneic breast cancer tumor growth, day 20 [mm3]',\n",
       " 'Cancer biology: Metastasis of implanted breast tumor in lymph node, cases with tumor metastasis [n]',\n",
       " 'Cancer biology: Metastasis of implanted breast tumor in pancreas, cases with tumor metastasis [n]',\n",
       " 'Infectious disease, immune function: Median survival time in log10 after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days in log10 * 100]',\n",
       " 'Immune system, aging: T-cell proliferative response (age-related decline), concavalin-A induced thymic T-cell response at 22-month-old in females (average of days 2 and 4)[unit]',\n",
       " 'Immune system, aging: Age-related T-cell decline, percentage of CD4-negative CD8-negative DN cells in thymus [%]',\n",
       " 'Immune system, aging: Age-related T-cell decline, percent of CD4-CD8 double positive cells in thymus [%]',\n",
       " 'Immune system, aging: T-cell decline during aging, percentage of CD25-negative/CD44-positive double negative (CD4(-)CD8(-)) cells in thymus at 22 months [%]',\n",
       " 'Immune system, aging: Age-related T-cell decline, percentage of CD25-positive CD44-negative DN cells in thymus [%]',\n",
       " 'Immune system, aging: Age-related T-cell decline, percentage of CD25-CD44 double negative thymocytes at 22 months in females [%]',\n",
       " 'Infectious disease, immune function: Normalized median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [ratio survival time BXD / survival time C57BL/6J * 100]',\n",
       " 'Infectious disease, immune function: Mean moribund body weight after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [g * 10]',\n",
       " 'Infectious disease, immune function: Mean moribund temperature after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [deg C * 10]',\n",
       " 'Immune system, cancer: Resistance to lymphoma tumors induced by ESb DBA/2 (H-2d) cell transplant [%]',\n",
       " 'Infectious disease, immune function, pulmonary system: H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM]',\n",
       " 'Infectious disease, immune function: MCP-1 (CCL2 or monocyte chemotactic protein-1) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney]',\n",
       " 'Infectious disease, immune system: Herpes simplex virus 1 (HSV-1) ocular pathogenesis, please add details on sex, innoculum, age, etc here [units]',\n",
       " 'Infectious disease, immune function: locomotor activity during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline]',\n",
       " 'Infectious disease, immune function: locomotor activity during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline]',\n",
       " 'Infectious disease, immune function: locomotor activity during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline]',\n",
       " 'Infectious disease, immune function: Temperature during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C]',\n",
       " 'Infectious disease, immune function: Temperature during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C]',\n",
       " 'Infectious disease, immune function: Mean temperature 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [deg C * 10]',\n",
       " 'Infectious disease, immune system, urogenital system: TNF-a at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] ',\n",
       " 'Infectious disease, immune function: KC (CXCL1; keratinocyte-derived chemokine at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney]',\n",
       " 'Infectious disease, immune function: MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney]',\n",
       " 'Infectious disease, immune system: IP-10 (Interferon gamma-induced protein 10 or CXLC10) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, kidney] ',\n",
       " 'Infectious disease, immune system: G-CSF (granulocyte colony stimulating factor) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney]',\n",
       " 'Infectious disease, immune system: Interleukin-6 (IL-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein]',\n",
       " 'Infectious disease, immune system: lipocalin-2 (LCN-2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney]',\n",
       " 'Infectious disease, immune system, urogenital system: Candida albicans titer in kidney (log) at 72 h after inoculation with 1 x 10^6 cfu (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue]',\n",
       " 'Infectious disease, immune system, central nervous system: Candida albicans titer in brain at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue]',\n",
       " 'Infectious disease, immune function: Serum glucose (unfasted) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [mg/dL serum)',\n",
       " 'Infectious disease, immune function: locomotor activity during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline]',\n",
       " 'Infectious disease, immune function: temperature during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset (difference from baseline, C)',\n",
       " 'Infectious disease, immune function: locomotor activity during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline]',\n",
       " 'Infectious disease, immune system, urogenital system: TNF-a (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] ',\n",
       " 'Infectious disease, immune system: Locomotor activity 60-72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline]',\n",
       " 'Infectious disease, immune function: Linear median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days]',\n",
       " 'Infectious disease, immune system: Locomotor activity (log) during h 60-72 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log]',\n",
       " 'Infectious disease, immune function: locomotor activity (log) during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log]',\n",
       " 'Infectious disease, immune function: locomotor activity (log) during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log]',\n",
       " 'Infectious disease, immune function: locomotor activity (log) during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log]',\n",
       " 'Infectious disease, immune function: locomotor activity (log) during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline. log]',\n",
       " 'Infectious disease, immune system, morphology: Body weight 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [g]',\n",
       " 'Infectious disease, immune function: MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidn',\n",
       " 'Infectious disease, immune system, protein expression: Lipocalin-2 (LCN-2) level in kidney 72 h after inoculation with 1 x 10^6 CFU Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein]',\n",
       " 'Infectious disease, immune system: IP-10 (Interferon gamma-induced protein 10 or CXLC10) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, log, kidney] ',\n",
       " 'Infectious disease, immune function: KC (CXCL1; keratinocyte-derived chemokine) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney]',\n",
       " 'Infectious disease, immune system: IL-6 (interleukin-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein]',\n",
       " 'Infectious disease, immune function: G-CSF (granulocyte colony stimulating factor) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney]',\n",
       " 'Infectious disease, immune function: MCP-1 (CCL2 or monocyte chemotactic protein-1) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney]',\n",
       " 'Cancer biology: Syngeneic breast cancer tumor growth at day 30 [mm3]',\n",
       " 'Infectious disease, immune function: locomotor activity (log) during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline, log]',\n",
       " 'Infectious disease, immune function: Temperature during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C]',\n",
       " 'Infectious disease, immune function: Temperature during h 60-72 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus ; immediately after light onset [difference from baseline, C]',\n",
       " 'Infectious disease, immune function: Weight loss after Francisella tularensis live vaccine strain (FTLVS) intratracheal [slope]',\n",
       " 'Infectious disease, immune system: Survival after Francisella tularensis live vaccine strain (FTLVS) intratracheal [coefficient]',\n",
       " 'Infectious disease, immune system, urogenital system: Candida albicans titer, renal, at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [CFU x 10^4 per gram tissue we',\n",
       " 'Infectious disease, immune function: Temperature during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset (difference from baseline, C) ',\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed and the % of BtcR+ cells in \",\n",
       " 'Infectious disease, immune system, central nervous system: Candida albicans titer in brain (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue ',\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and PMNs we\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed and the % of CD4+/BTcR+ cell\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o\",\n",
       " 'Infectious disease, immune function: Weight loss after Francisella tularensis live vaccine strain (FTLVS) intratracheal [percent]',\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o\",\n",
       " 'Cancer biology: Leukocyte infiltration in metastatic breast tumor on day 12 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index]',\n",
       " 'Immune system: Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone D9 [thymidine uptake cpm]',\n",
       " 'Infectious disease, immune system: Leishmania L. mexicana skin lesion diameter in females [mm]',\n",
       " 'Cancer biology: Syngeneic breast cancer tumor growth, day 35 [mm3]',\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Flow cytometry was performed on the BAL cells from male mice and gated on CD8+/bTcR+/CD69+ expressed as %. \",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), CD8+ T cell in bronchioalveolar lavage (BAL) samples 20 hours after last exposure exposure [%]\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells in males \",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), T cells in bronchioalveolar lavage (BAL) samples 20 hours after last exposure exposure in males (BXD32 wins\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease) and analyzed 20hrs after the last exposure. Neutrophils were identified by flow cytometry and analysis of F\",\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Alveolitis was measured by cell counting using trypan blu\",\n",
       " 'Cancer biology, immune system: T cell infiltration at tumor site in breast cancer cells on day 1 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index]',\n",
       " 'Immune system: Antigenic activity of irradiated BXD spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone E4.3 [thymidine uptake cpm]',\n",
       " 'Infection disease, immune function: Cox-Hasty trait 1',\n",
       " 'Immune system: Antigenic activity of irradiated BXD spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone TGVH 9 [thymidine uptake cpm]',\n",
       " 'Immune system: Antigenic activity of irradiated BXD spleen cells for Thy1+CD3+CD4+CD8- T-cell clone TGVH32 [thymidine uptake, cpm]',\n",
       " 'Immune system: Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4-CD8+ H-2(d) specific T-cell clone F10 ECK [thymidine uptake cpm]',\n",
       " 'Immune system: Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone (11.1B/c) [thymidine uptake cpm]',\n",
       " 'Immune system: Anti-F antigen (liver protein) titer, experiment 2, log10 of the reciprocal of the dilution of serum required to bind 50% of the labeled antigen [log binding]',\n",
       " 'Immune system: Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- Mls(a) specific T-cell clone F5J10 [thymidine uptake cpm]',\n",
       " 'Immune system, morphology: Thymus weight of females after 7 weeks of chronic mild stress (CMS) followed by an acute stressor (30 min restraint) [g]',\n",
       " 'Cancer biology: Apoptosis of breast tumor cells on day 12 (0 means no apoptosis infiltration and no destruction of implanted tumor cell and 4 means most severe) [index]',\n",
       " 'Immune system: Graft-vs-host reaction, antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone 11.4 B/c [thymidine uptake, cpm]',\n",
       " 'Cancer biology, immune system: T cell infiltration at tumor site in breast cancer cells on day 30 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index]',\n",
       " 'Cancer biology: Mixed lymphocyte reaction (MLR) with BALB/c spleen cells [cpm stimulated/cpm unstimulated]',\n",
       " 'Immune system: T-cell anergy induced by Bacillus Calmette_¾_Gu\\x90©rin tuberculosis vaccine (BCG), delayed type hypersensitivity in footpad increments [mm]',\n",
       " 'Cancer biology: Tumor growth 7 weeks post-implantation [mm3]',\n",
       " 'Cancer biology: Apoptosis of breast tumor cells on day 30 (0 means no apoptosis infiltration and no destruction of implanted tumor cell and 4 means most severe) [index]',\n",
       " 'Cancer biology: Leukocyte infiltration in metastatic breast tumor on day 5 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index]',\n",
       " 'Immune system: Anti-F antigen (liver protein) titer, experiment 1, log10 of the reciprocal of the dilution of serum required to bind 50% of the labeled antigen [log binding]',\n",
       " 'Cancer biology: Tumor growth and size, 2 weeks post-implantation [mm3]',\n",
       " 'Immune system: Proliferation of T cell clone (A9.4 subclone) with 50 ug/ml KLH experiment 1, 5X10E5 stimulator cells [cpm]',\n",
       " 'Infectious disease, immune system: Respiratory syncytial virus (RSV) response, viral load in whole lung (NS1 gene) 4 days after infection of 5 day old neonates [mean ratio of NS1 to reference NS1]',\n",
       " 'Cancer biology: Tumor growth 3 weeks post-implantation [mm3]',\n",
       " 'Immune system: Proliferation of T cell clone (A9.4 subclone) without 50 ug/ml KLH experiment 1 [cpm]',\n",
       " 'Endocrinology: Serum thyroxine (T4), total serum T4 content [ug/100ml]',\n",
       " 'Endocrinology, metabolism: Serum thyroxine (T4) content (free) [ug/100ml]',\n",
       " 'Immune system: T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in pool of 5 responders [units]',\n",
       " 'Immune system: T-cell response, cytotoxic T lymphocytes, Mean 51Cr release at 10:1 E:T after spleen cells primed and boosted in MLC in pool of 5 responders [units]',\n",
       " 'Immune system: T-cell response, antibody-dependent cell-mediated cytotoxicity, 51Cr release at 5:1 E:T after spleen cells primed and boosted in mixed lymphocyte culture (MLC) in pool of five responders [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 5:1 E:T after spleen cells primed and boosted in MLC in responder 2 [units]',\n",
       " 'Immune system: Proliferation of T cell clone (A9.4 subclone) without 50 ug/ml KLH experiment 2 [cpm]',\n",
       " 'Immune system: Proliferation of T cell clone (A9.4 subclone) with 50 ug/ml KLH experiment 2, 1X10E6 stimulator cells [cpm]',\n",
       " 'Immune system: T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in responder 1 [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 10:1 E:T after spleen cells primed and boosted in MLC in responder 1 [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 5:1 E:T after spleen cells primed and boosted in MLC in responder 1 [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in responder 2 [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 10:1 E:T after spleen cells primed and boosted with mixed lymphocyte culture in responder 2 [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in responder 3 [units]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 10:1 E:T after spleen cells primed and boosted in MLC in responder 3 [units]',\n",
       " 'Cancer biology:Leukocyte infiltration in metastatic breast tumor on day 30 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index]',\n",
       " 'Immune sytstem: T-cell response, cytotoxic T lymphocytes, 51Cr release at 5:1 E:T after spleen cells primed and boosted in MLC in responder 3 [units]',\n",
       " 'Cancer biology: Growth of syngeneic breast cancer tumors day 50 [mm3]',\n",
       " 'Cancer biology: Growth of syngeneic breast cancer tumors day 45 [mm3]',\n",
       " 'Cancer biology: Growth of syngeneic breast cancer tumors day 40 [mm3]',\n",
       " \"Immune system, infectious disease: S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and B cells\",\n",
       " 'Infectious disease, immune system: Hematocrit 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [proportional packed cell volume of RBCs in whole blood]',\n",
       " 'Blood chemistry, infectious disease, immune system: White blood cell (WBC) count 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [number per ul of whole blood]',\n",
       " 'Infectious disease, immune system: Ratio of number of neutrophil to lymphocyte ratio at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [neutrophil to lymphocyte ratio, whole b',\n",
       " 'Infectious disease, immune system: Leishmania L. mexicana lesion diameter after subcutaneous injection in males (this entry is missing data) [mm]',\n",
       " 'Infectious disease, immune system: Bovine spongioform encephalopathy (prion disease, mouse-adapted scrapie strain ME7), primary transmission incubation period in females [days]',\n",
       " 'Infectious disease, immune system: Burkholderia pseudomallei (strain 1026b, 100 CFU intranasal under isoflurane) survival to 11-days in 12_¾_13 week-old males and females [%]',\n",
       " 'Cancer biology, immune system: T cell infiltration at tumor site in breast cancer cells on day 5 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index]',\n",
       " 'Immunology, infectious disease: Staphloccocus pyogenes (sq injection of 1.0x10x8 CFU) survival index in males and females injected at 10_¾_16 week of age (death before day 3 = 1, death from 3 to 7 = 2, death after day 7 =3) [index]']"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(other_data[3][1][other_data[3][1][\"Category\"] == \"Immune\"].sort_values(\"Strains\", ascending=False)[\"Phenotype\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "other_data[3][1][other_data[3][1][\"Category\"] == \"Activity\"].sort_values(\"Strains\", ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PhenoID</th>\n",
       "      <th>PhenoID.1</th>\n",
       "      <th>RecordID</th>\n",
       "      <th>Phenotype</th>\n",
       "      <th>Shown_pheno</th>\n",
       "      <th>Category</th>\n",
       "      <th>Category_ID</th>\n",
       "      <th>color</th>\n",
       "      <th>Phenotype_post</th>\n",
       "      <th>Phenotype_pre</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Senior.Author</th>\n",
       "      <th>Abbreviation</th>\n",
       "      <th>Quantitive.trait</th>\n",
       "      <th>Tissues</th>\n",
       "      <th>Diet</th>\n",
       "      <th>Strains</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>1601</td>\n",
       "      <td>X893</td>\n",
       "      <td>893</td>\n",
       "      <td>10866</td>\n",
       "      <td>Infectious disease, immune system: H5N1 influe...</td>\n",
       "      <td>H5N1 influenza A virus survival time (10^4 EID...</td>\n",
       "      <td>Immune</td>\n",
       "      <td>1602.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Infectious disease, immune system: H5N1 influe...</td>\n",
       "      <td>Infectious disease, immune system: H5N1 influe...</td>\n",
       "      <td>Boon ACM, deBeauchamp J, Hollmann A, Luke J, K...</td>\n",
       "      <td>Webby</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Yes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>69</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     PhenoID  PhenoID.1  RecordID  \\\n",
       "1601    X893        893     10866   \n",
       "\n",
       "                                              Phenotype  \\\n",
       "1601  Infectious disease, immune system: H5N1 influe...   \n",
       "\n",
       "                                            Shown_pheno Category  Category_ID  \\\n",
       "1601  H5N1 influenza A virus survival time (10^4 EID...   Immune       1602.0   \n",
       "\n",
       "      color                                     Phenotype_post  \\\n",
       "1601    5.0  Infectious disease, immune system: H5N1 influe...   \n",
       "\n",
       "                                          Phenotype_pre  \\\n",
       "1601  Infectious disease, immune system: H5N1 influe...   \n",
       "\n",
       "                                                Authors Senior.Author  \\\n",
       "1601  Boon ACM, deBeauchamp J, Hollmann A, Luke J, K...         Webby   \n",
       "\n",
       "     Abbreviation Quantitive.trait Tissues Diet  Strains  \n",
       "1601          NaN              Yes     NaN  NaN       69  "
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "other_data[3][1][other_data[3][1][\"Phenotype\"] == \"Infectious disease, immune system: H5N1 influenza A virus survival time (10^4 EID-50 of HK213 virus in 30 microliters saline) [days, max to 30]\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Eye, visual system, morphology: Eye weight, fresh unfixed, corrected for age [mg]',\n",
       " 'Central nervous system, morphology: Forebrain weight, adjusted by age, sex, body weight and BXD epoch [mg]',\n",
       " 'Central nervous system, cardiovascular system: Infarct volume in neocortex, binary score, following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), 24 ',\n",
       " 'Central nervous system, cardiovascular system: Infarct volume in neocortex (log transformed) following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), ',\n",
       " 'Central nervous system, cardiovascular system: Infarct volume in neocortex following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), 24 hr survival (al',\n",
       " 'Eye, visual system: Iris pigmentation (all ages) [ordinal scale, 0=pigmented, 4=light, dispersed]',\n",
       " 'Genetics, cofactor: GABRA2 receptor expression status where 1 = normal high expression and 0 = low expression as seen in C57BL/6J after 1990 [level]',\n",
       " 'Central nervous system, morphology: Midsagittal area of the corpus callosum, corrected for shrinkage, age, sex, brain weight, epoch [mm2]',\n",
       " 'Central nervous system, development, morphology: Ectopia incidence in the neocortex (cerebral cortex) of adults, affected cases detected in the Mouse Brain Library [2x arcsine of % cases]',\n",
       " 'Central nervous system, morphology:Midsagittal area of the corpus callosum corrected for shrinkage [mm2]',\n",
       " 'Central nervous system, eye, visual system gene expression: Retinal ganglion cell expression PCA eigengene generated using the Full HEI Retina Illumina RankInv database (PC01, 37% of variance) and a set of 7 genes that covary well with RGC Trait 10600 (Ab',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), all ages (1 to 30 months old), both sexes, average of left and right eyes',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 5.1 to 9 months old, both sexes, average of left and right eyes',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec]',\n",
       " 'Metadata, cofactor: Age at death (average) of hippocampal samples (use only with UTHSC BXD Aged Hippocampus Affy expression data sets) [days]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (BXD102 winterized from 21.008 +-19.93 to 3.0 and BX',\n",
       " 'Central nervous system, gene expression: Neurexin 1 (Nrxn1) expression in hippocampus, first principal component generated using all coding exon probe sets and UMUTAffyExon_0209_RMA data [relative residual concentration]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec]',\n",
       " 'Central nervous system, gene expression: Erbb4 mRNA expression in hippocampus (receptor tyrosine-protein kinase erbB-4), first principal component generated using exon probe sets and UMUTAffyExon_0209_RMA data [relative residual concentration]',\n",
       " 'Central nervous system, gene expression: Trpc3 mRNA expression in hippocampus (transient receptor potential cation channel, subfamily C, member 3), first principal component generated using exon probe sets and with high expression (<8.5, covaries well wit',\n",
       " \"Central nervous system, gene expression: Eigentrait for TRPC3 expression generated using exon 1, exon 1 or 5' UTR, 3' UTR, exon 6, and exon 8 [PC score]\",\n",
       " 'Central nervous system, gene expression: Trpc3 mRNA expression in hippocampus (transient receptor potential cation channel, subfamily C, member 3), first principal component generated using exon probe sets 5115892 (exon 6), 4650080 (exon 5), 4674708 (exon',\n",
       " \"Central nervous system, gene expression: Mep1b eigentrait generated using probe sets 4972258 (exon 7), 4627542 (exon 9), 4977437 (5' UTR), 5091054 (exon 10), 4557674 (exon 11), all verified to be SNP-free and with expression greater than 7 unit using UMUT\",\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), all ages (1 to 30 months old), both sexes, average of left and right eyes [mmHg]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (1.8 g/kg ip), anxiety assay in ethanol-treated (NOE) group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks/',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, gene expression: Kcnq5 mRNA expression in hippocampus (Kv7.5, potassium voltage-gated channel, subfamily Q, member 5, M-current, slowly activating muscarinic acetylcholine receptor sensitive), first principal component generated us',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks]',\n",
       " 'Central nervous system, gene expression: Tnik mRNA expression in hippocampus (TRAF2 and NCK interacting kinase), first principal component generated using exon probe sets and UMUTAffyExon_0209_RMA data [relative residual concentration]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) in the RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam break',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time]',\n",
       " 'Central nervous system, pharmacology, behavior: Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks]',\n",
       " 'Eye, visual system: Iris pigmentation at 6-9 months, males and females [ordinal score, 0=normal, 4=light, dispersed]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 6 to 9 months old, both sexes, average of left and right eyes [mmHg]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), all ages (1 to 30 months old), both sexes, average of left and right eyes. (BXD48 and BXD96 are merged; BXD65 and BXD97 are merged; BXD73, BXD80 and BXD103 are merged). [mmHg]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec]',\n",
       " 'Reproduction: Breeding performance, litter size at birth (within 24 hrs) at the Jackson Laboratory (BXD29-Tlr4 not entered but value is 4.25+/-0.639 n=8), Mouse Phenome Database traits MDP:42302, 423033, and 44403 (TyJ in standard barrier room, RwwJ set i',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, morphology: Neocortex total cell number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Central nervous system, morphology: Neocortex non-neuron number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " '1416531_at (Gsto1) Residual [partial correlation with markers rs13483647 and rs13483649 using Hippocampus Consortium M430v2 (Jun06) RMA Database] ',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time]',\n",
       " 'Central nervous system, morphology: Neocortex volume, shrinkage corrected, bilateral, both sexes between 50 and 300 days, using the Cavalieri probe [mm3]',\n",
       " 'Central nervous system, morphology: Neocortex neuron cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (data for BXD11 (16.419 +/-15.',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 5.1 to 9 months old, both sexes, average of left and right eyes. (BXD48 and BXD96 are merged; BXD65 and BXD97 are merged; BXD73, BXD80 and BXD103 are merged). [mmHg]',\n",
       " 'Central nervous system, morphology: Neocortex non-neuronal cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, morphology: Neocortex total cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec]',\n",
       " 'Central nervous system, morphology: Neocortex neuron number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Central nervous system, eye, visual system gene expression: Retinal ganglion cell expression PCA eigengene generated using the DoD CDMRP Retina Affy MoGene 2.0 ST (May15) RMA Gene Level database (PC03, 8% of variance) and a set of 73 known and putative RG',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time]',\n",
       " 'Central nervous system, morphology: Lateral septum volume, adult both sexes (MBL samples), morphometric point counting estimate from serial sections (without corrections) [mm3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated (0.18 ml/kg ip, NOS group), time in open quadrants only during last 5 min of test using an elevated zero maze for 60- to 120-day-old females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, morphology: Total cell number in cerebral neocortex of adults (neurons, glial cells, endothelial cells), bilateral (direct 3D counting method) [millions] ',\n",
       " 'Central nervous system, morphology: Septum volume corrected for shrinkage, age, sex, plane of section, brain weight, and epoch [mm3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 2.1 to 5 months old, both sexes, average of left and right eyes',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) for RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, morphology: Neuron number in cerebral neocortex of adults, bilateral (direct 3D counting method) [millions] ',\n",
       " 'Central nervous system, behavior: Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec]',\n",
       " 'Central nervous system, morphology: Non-neuronal cell number in cerebral neocortex of adults, bilateral (direct 3D counting method) [millions] ',\n",
       " 'Eye, visual system: Iris pigmentation score at 10-13 months in males and females [ordinal scale, 0=full pigmentation, 4=light, dispersed]',\n",
       " 'Eye, visual system: Iris pigmentation at 3-5 months in males and females [ordinal scale, 0=full pigmentation, 4=light, dispersed]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) total cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) neuron cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) volume, shrinkage corrected, bilateral, both sexes between 50 and 300 days, using the Cavalieri probe [mm3]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) non-neuronal number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Central nervous system, morphology: Cerebellum residual weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, body weight, and epoch (Hager et al., 2012) [residual mg]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) neuron number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Eye, visual system, physiology, aging: Intraocular pressure (IOP), more than 13 months old, both sexes, average of left and right eyes',\n",
       " 'Central nervous system, morphology: Cerebellum residual weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, and body weight [residual mg]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) total cell number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) non-neuronal cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during whole 10 min test [% time]',\n",
       " 'Central nervous system, morphology: Neocortex neuron number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 10 to 13 months old, both sexes, average of left and right eyes [mmHg]',\n",
       " 'Central nervous system, pharmacology, behavior: Anxiety assay, ethanol treated (1.8 g/kg ip) (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, morphology: Neocortex non-neuronal number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during first 5 min [% time]',\n",
       " 'Central nervous system, morphology: Neocortex total cell number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Infectious disease, immune system: H5N1 influenza A virus mortality rate 30 days after infection (10^4 EID-50 of HK213 virus in 30 microliters saline) [% death]',\n",
       " 'Central nervous system, morphology: Neocortex neuron cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Infectious disease, immune system: H5N1 influenza A virus survival time (10^4 EID-50 of HK213 virus in 30 microliters saline) [days, max to 30]',\n",
       " 'Central nervous system, morphology: Neocortex non-neuronal cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, morphology: Neocortex total cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, pharmacology, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percent time]',\n",
       " 'Reproduction, urogenital system, morphology: uterine body length at maturity, adjusted for age, body weight, dissector, source, and days in fixative [cm]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 3 to 5 months old, both sexes, average of left and right eyes [mmHg]',\n",
       " 'Reproduction, urogenital system, morphology: ovarian weight at maturity, average of unilateral values, adjusted for age, birth weight, dissector, source, and days in fixative [mg]',\n",
       " 'Reproduction, urogenital system, morphology: uterine horn length at maturity, average of unilateral values, adjusted for age, body weight, dissector, source, and days in fixative [cm]',\n",
       " 'Reproduction, urogenital system, morphology: uterine body width at maturity, adjusted for age, body weight, dissector, source, and days in fixative [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) volume, shrinkage corrected and corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using Cavalieri probes [mm3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) neuron cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) non-neuronal cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) total cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Pain sensitivity, vocalization threshold to mild foot shock for males and females [mA]',\n",
       " 'Reproduction, urogenital system, morphology: Uterus body width at maturity, unadjusted for body weight, age, or parity [cm]',\n",
       " 'Reproduction, urogenital system, morphology: Uterus body length, unadjusted for body weight, age, or parity [cm]',\n",
       " 'Reproduction, urogenital system, morphology: Uterus horn length at maturity (average of right and left sides), unadjusted for body weight, age, or parity [mg]',\n",
       " 'Reproduction, urogenital system, morphology: Uterus weight at maturity, bilateral, unadjusted for body weight, age, or parity [mg]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time]',\n",
       " 'Reproduction: Breeding performance at the Regional Biocontainment Facility, Memphis (UTHSC 2010-2011) [ordinal scale, 0=poor, 1=fair, 2=good]',\n",
       " 'Morphology, cofactor : Body weight of young adult females before immunization with TSHR A-subunit (human) adenovirus (see Traits 16314 by McLachlan and colleagues) [g]',\n",
       " 'Immune system: ELISA-3x, IgG class antibody binding to TSHR A-subunit protein in ELISA 4 weeks after 3 immunizations with TSHR A-subunit adenovirus [OD490 nm]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) neuron number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) non-neuronal number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Immune system, endocrinology: Serum inhibition of TSH binding to the TSHR 4 weeks after 3 immunizations with TSHR A-subunit adenovirus in young adult females [% inhibition]',\n",
       " 'Central nervous system, morphology: Striatum (caudate putamen) total cell number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6]',\n",
       " 'Reproduction: Breeding performance, litter size at weaning (circa 20 days) at the Jackson Laboratory (BXD29-Tlr4 not entered but value is 3.11+/-0.1.16 with n=8), Mouse Phenome Database traits MDP:42303, 42304, and 44404 (minimum SE for n<4 set to 1.0) [n',\n",
       " 'Eye, visual system, aging: Iris pigmentation score in old males and females (>13 months) [ordinal scale, 0=full pigmentation, 4=light, dispersed]',\n",
       " 'Immune system, endocrinology: serum inhibition of TSH binding to the TSHR before immunization [% inhibition] ',\n",
       " 'Central nervous system, morphology: Hippocampus residual weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, body weight, and epoch (Hager et al., 2012) [residual mg]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 1 to 2 months old, both sexes, average of left and right eyes [mmHg]',\n",
       " 'Endocrine system, thyroid: T4-3x, serum thyroxine (T4) 4 weeks after 3 immunizations of females with TSHR A-subunit adenovirus [micrograms/dL]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time]',\n",
       " 'Central nervous system, gene expression: Eigentrait for Cadm1 expression generated from probes that are SNP-free across BXDs using BXD Aged Hippocampus rev3 Affy Mouse Gene 1.0 ST (Sep12) RMA [PC Score]',\n",
       " 'Central nervous system, pharmacology, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg i.p.] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min (data for BXD77 (4.463 +/-',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight, males and females (unilateral, uncorrected, 2006) [mg]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 1 to 2 months old, both sexes, average of left and right eyes [mmHg]',\n",
       " 'Del T4-3x, serum thyroxine (T4) 4 weeks after 3 immunizations of female mice with TSHR A-subunit adenovirus minus baseline T4 [micrograms/dL] ',\n",
       " 'Reproduction, urogenital system, morphology: Uterus and ovary weight at maturity, bilateral, unadjusted for body weight, age, or parity [mg]',\n",
       " 'Reproduction, urogenital system, morphology: Ovary weight at maturity, unilateral (average of right and left), unadjusted for body weight, age, or parity [mg]',\n",
       " 'Endocrine system, thyroid: T4-0x, serum thyroxine (T4) before immunization with TSHR A-subunit adenovirus [micrograms/dL]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight (unilateral, regressed to eliminate variance due to age, body weight, and sex in 2006) [mg]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 2.1 to 5 months old, both sexes, average of left and right eyes. (BXD48 and BXD96 are merged; BXD65 and BXD97 are merged; BXD73, BXD80 and BXD103 are merged). [mmHg]',\n",
       " 'Central nervous system, behavior, somatosensory system: Pain sensitivity, vocalization threshold to mild foot shock for males [mA]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 9.1 to 13 months old, both sexes, average of left and right eyes. (BXD48 and BXD96 are merged; BXD65 and BXD97 are merged; BXD73, BXD80 and BXD103 are merged). [mmHg]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal total weight for females [mg]',\n",
       " 'Central nervous system, behavior: Central motor pattern generator, lick count for water over 20 minutes (MS160 lickometer), male and female adults [n/20 min]',\n",
       " 'Eye, visual system, physiology, aging: Intraocular pressure (IOP), more than 13 months old, both sexes, average of left and right eyes. (BXD48 and BXD96 are merged; BXD65 and BXD97 are merged; BXD73, BXD80 and BXD103 are merged). [mmHg]',\n",
       " 'Reproduction, urogenital system, morphology: uterine weight at maturity, adjusted for age, body weight, dissector, source, and days in fixative [mg]',\n",
       " 'Cardiovascular system, morphology: Heart weight, young adult males and females, adjusted by age, sex, and body weight (BXD19 winsorized from 80.7 to 118) [mg]',\n",
       " 'Cardiovascular system, morphology: Heart weight, young adult males and females, unadjusted (BXD19 winsorized from 101.4 to 118) [mg]',\n",
       " 'Central nervous system, behavior: Central motor pattern generation (CPG), mean primary interlick interval (MPI, time between licks) for 0.1 M sucrose over 20 min (Davis MS160 lickometer), male and female adults [mSec]',\n",
       " 'Central nervous system, behavior: Central motor pattern generation (CPG), mean primary interlick interval (MPI, time between licks) for water over 20 min (Davis MS160 lickometer), male and female adults [mSec]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal total weight for males [mg]',\n",
       " 'Eye, visual system, physiology, aging: Intraocular pressure (IOP), more than 13 months old, both sexes, average of left and right eyes [mmHg]',\n",
       " 'Central nervous system, behavior: Pain sensitivity, vocalization threshold to mild foot shock for females [mA]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona fasciculata width [um]',\n",
       " 'Cardiovascular system, morphology: Heart weight without statistical adjustment (C57BL/6J data looks anomalous) [mg]',\n",
       " 'Central nervous system, behavior: Central motor pattern generation (CPG), volume per lick, water over 20 min (MS160 lickometer), male and female adults [ul]',\n",
       " 'Central nervous system, behavior: Central motor pattern generation, lick count for 0.1 M sucrose over 20 minutes (MS160 lickometer), male and female adults [n/20 min]',\n",
       " 'Reproduction: Breeding performance, interval between litters at the Jackson Laboratory (BXD29-Tlr4 not entered but value is 4.96 +/- 0.58 n=7), Mouse Phenome Database traits MDP:44301 and 42302 (TyJ in standard barrier room, RwwJ set in SPF maximum barrie',\n",
       " 'Central nervous system, behavior: Central motor pattern generation, volume per lick, 0.1 M sucrose over 20 minutes (MS160 lickometer), male and female adults [ul]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal medulla width [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal X-zone width for females [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona glomerulosa width for females [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona fasciculata width for females [um]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 9 to 13 months old, both sexes, average of left and right eyes (BXD44 winsorized from 21.8 to 19.4, BXD38 winsorized from 9.58 to 10.9, BXD48 outlier deleted (9.300 +/- 0.768 SE), BXD80/73a and B',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal width (total) for females [um]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal medulla width for females [um]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [% time]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip)(RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks/sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg ip] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females over 10 min [beam breaks/sec]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona intermedia width for females [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona reticularis width for females [um]',\n",
       " 'Central nervous system, behavior: Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec]',\n",
       " 'Immune system, endocrine system: TBI-2x, serum inhibition of TSH binding to the TSHR 1 week after 2 immunizations with TSHR A-subunit adenovirus [% inhibition]',\n",
       " 'Trait 1b',\n",
       " 'Eye, visual system: Iris pigmentation at 1-2 months in males and females [ordinal scale, 0=full pigmentation, 4=light]',\n",
       " 'Immune system: ELISA-2x, IgG class antibody binding to TSHR A-subunit protein in ELISA 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus [OD 490 nm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for females [n fecal boli]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for females [n/15 min test]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for females (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone)',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for females [ordinal scale, 0=control level, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) 150-165 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [n beam breaks]',\n",
       " 'Endocrine system, thyroid: T4-2x: serum thyroxine (T4) 1 week after 2 immunizations with TSHR A-subunit adenovirus [micrograms/dL]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injections in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Enodocrine system, thyroid: Del T4-2x, serum thyroxine (T4) 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus minus baseline T4 [micrograms/dL]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males and females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males and females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males and females [ordinal scale, 0=control level, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males and females [n/15 min test]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males and females [n fecal boli]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males and females [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males and females between first and second injections [difference in n/1 hr test, positive values indicate sensitiza',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for females between first and second injections [difference in n/1 hr test, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [cm, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [n beam breaks, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for females [difference in cm/1 hr test, positive values indicate sensitiz',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for females [n beam breaks/60 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males and females (last 15 min of morphine test (165-180 min) minus first 15 min after',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks]',\n",
       " 'Eye, visual system, physiology: Intraocular pressure (IOP), 1 to 2 months old, both sexes, average of left and right eyes. (BXD48 and BXD96 are merged; BXD65 and BXD97 are merged; BXD73, BXD80 and BXD103 are merged). [mmHg]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [cm, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [n beam breaks, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males and females [difference in cm/1 hr test, positive values indicate',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males and females [n beam breaks/60 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 30-45 min in the periphery for females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45-60 min in the center for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30-45 min in the center for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from15-30 min in the center for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-15 min in the center for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 45-60 min for females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 30-45 min for females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-15 min for females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 45-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 30-45 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 15-30 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-15 min for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 15-30 min in the periphery for females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 45-60 min in the periphery for females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior, neuropharmacology: Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-60 min for females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, percentage of locomotion in the periphery for females [%]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-60 min in the center for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior, neuropharmacology: Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [n beam breaks]',\n",
       " 'Trait 1a',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal X-zone width for males [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona fasciculata width in young adult males [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona glomerulosa width for males [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal width (total) for males [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal medulla width for males [um]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight of males (unilateral, adjusted for age and body size) [mg]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight of males (unilateral) [mg]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight of females (unilateral, corrected for age and body weight)[mg]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight of adult females, unilateral, without any adjustments [mg]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [cm]',\n",
       " 'Endocrinology, morphology: Adrenal weight (right) of males and females [mg]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [cm]',\n",
       " 'Endocrinology, morphology: Adrenal weight (left) of males and females [mg]',\n",
       " 'Endocrinology, morphology: Adrenal weight (right) of females [mg]',\n",
       " 'Endocrinology: Adrenal weight (left) of females [mg]',\n",
       " 'Endocrinology, morphology: Adrenal weight (right) of males [mg]',\n",
       " 'Endocrinology, morphology: Adrenal weight (left) of males [mg]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona reticularis width for males [um]',\n",
       " 'Endocrinology, neuroendocrine system, morphology: Adrenal zona intermedia width for males [um]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, urinations for females [n/test period]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center from 0-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45-60 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30-45 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15-30 min for females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-15 for females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion locomotion in the periphery from 15-30 for males and females in the morphine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 15-30 min for females [cm]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress, difference between stress and control groups time in open arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3C right)[sec]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 15-30 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-15 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 45-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 30-45 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, percentage of locomotion in the periphery for males and females [%]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 15-30 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-15 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (CVS for four weeks) freezing to tone after fear conditioning, nine exposures to a 85 dB 3KHz tones in singly-housed 3-4 month-old males (Figure 2C middle)[sec]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (unstressed control) freezing to tone after fear conditioning, nine exposures to a 85 dB 3KHz tones in singly-housed 3-4 month-old males (Figure 2C left)[sec]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 30-45 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 45-60 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 45-60 min in the periphery for males and females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 30-45 min in the periphery for males and females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 15-30 min in the periphery for males and females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 0-15 min in the periphery for males and females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress, difference between stress and control groups time in closed arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3B right)[sec]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (CVS for four weeks) time in closed arm of an elevated plus (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3B middle)[sec]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (unstressed control) time in closed arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3B left)[sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (CVS for four weeks) time in open arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3C middle)[sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (unstressed control) time in open arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3C left)[sec]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress, difference between stress and control groups freezing to tone after fear conditioning, nine exposures to a 85 dB 3KHz tones in singly-housed 3-4 month-old males (Figure 2C right)[sec]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males and females [n beam breaks]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress, difference between stress and control groups locomoter distance in an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3A right)[m]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (CVS for four weeks) locomoter distance in an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3A middle)[m]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion from 0-15 min in the periphery for females in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [cm]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (unstressed control) locomoter distance in an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3A left)[m]',\n",
       " 'Central nervous system, behavior: Novel open field behavior,vertical activity (rears) from 0-15 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15-30 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from min 30-45 for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, urinations for males and females [n/test period]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress, difference between stress and control groups freezing during training (Med Associates chamber, 2 sec 0.75 mA shock, 85 dB 3KHz tone, 4 tone-shock pairings) in singly-housed 3-4 month-',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (CVS for four weeks) freezing during training (Med Associates chamber, 2 sec 0.75 mA shock, 85 dB 3KHz tone, 4 tone-shock pairings) in singly-housed 3-4 month-old males (Figure 2A midd',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (unstressed control) freezing during training (Med Associates chamber, 2 sec 0.75 mA shock, 85 dB 3KHz tone, 4 tone-shock pairings) in singly-housed 3-4 month-old males (Figure 2A left',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males and females [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-180 min after injection (total open field activity over 3 hour test) for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males [n/15 min test]',\n",
       " 'Central nervous system, pharmacology: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) [',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males [n fecal boli]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for males in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min after injection (total vertical activity over 3 hour test) for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males [ordinal scale, 0=control level, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion locomotion in the periphery from 15-30 min for males in the morphine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip) and naloxone response (30 mg/kg ip), naloxone-induced withdrawal after morphine, vertical activity (rears) from 0-15 min for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males [ordinal scale, 0=no effect, 3=max]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males between first and second injections [difference in n/1 hr test, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males [n beam breaks]',\n",
       " 'Urogenital system, kidney, morphology: Kidney weight of males (raw data, unadjusted) [mg]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [n beam breaks/15 min]',\n",
       " 'Infectious disease, immune system: Malaria infection lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old males and females (0 = 100% resistant, 1 = 100% susceptible) [fraction of cohort that survives]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males [n beam breaks/60 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males [difference in cm/1 hr test, positive values indicate sensitizat',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [n beam breaks, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [cm, positive values indicate sensitization]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [n beam breaks/15 min]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males [n beam breaks] ',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion from 0-15 min in the periphery for males in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 15-30 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 30-45 min for males [n beam breaks] ',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 45-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-15 min for males [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 15-30 min for males [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 30-45 min for males [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 45-60 min for males [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior: Novel open field behavior, locomotion in the periphery from 0-15 min for males in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 15-30 min for males in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 30-45 min for males in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 45-60 min for males in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion from 15-30 min in the periphery for males in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion from 30-45 min in the periphery for males in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion from 45-60 min in the periphery for males in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males [n beam breaks]',\n",
       " 'Central nervous system, adult neurogenesis: Proliferation of BrdU-labeled cells in subgranular zone, 1h BrdU injection, unadjusted data [n cells]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0-15 min for males [n beam breaks]',\n",
       " 'Central nervous system, adult neurogenesis: Newly generated BrdU-labeled cells in young adult rostral migratory stream (RMS), unadjusted data [N per mm of RMS length]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [cm]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, percentage of locomotion in the periphery for males [%]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-15 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males [cm]',\n",
       " 'Central nervous system, urogenital system, behavior: Novel open field behavior, urinations for males [n/test period]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15-30 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30-45 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Cocaine response (3 x 3.2 mg/kg ip, days 2, 3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (day 5 minus day 1',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Cocaine response (3 x 3.2 mg/kg ip, days 2, 3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (day 5 minus day 1) for males',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for males and females [%]',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Cocaine response (3 x 3.2 mg/kg ip, days 2, 3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on day 5 for males and females [sec]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Cocaine response (3 x 3.2 mg/kg ip, days 2, 3, 4), conditioned place preference (CPP), time in drug-paired compartment on day 5 for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior, learning and memory: Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for males and females [sec]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Novel open field behavior, locomotion in the periphery from 0-60 min for males [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in open arms of an elevated plus maze for males and females [sec]',\n",
       " 'Central nervous system, behavior, learning and memory: Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for males [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for males [sec] ',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males and females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, entries into open arms of a plus maze for males and females [n]',\n",
       " 'Central nervous system, behavior: Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for males [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males and females [n]',\n",
       " 'Central nervous system, behavior: Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for males [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [sec]',\n",
       " 'Central nervous system, behavior: Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for females [%]',\n",
       " 'Central nervous system, behavior: Saline control response (dose ip), motor coordination effects, difference in time on rotarod between training session and saline for males and females [sec]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), time on rotarod after saline minus time on rotarod after ethanol for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males females [sec]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, and 4), conditioned place preference (CPP), change in percentage of time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [% cha',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in middle of an elevated plus maze for males and females [sec]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males and females [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in closed arms of an elevated plus maze for males and females [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percentage of time in open arms of plus maze for males and females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males and females [%]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males and females [mg/dl XX min after injection]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males and females [%]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion from 15-20 min after injection for males and females [cm] ',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males and females [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [% chan',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [sec]',\n",
       " 'Central nervous system, behavior: Motor coordination, rotarod performance, untreated training trial for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Cocaine response (3 x 3.2 mg/kg ip, Days 2, 3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for males [sec]',\n",
       " 'Musculoskeletal system, morphology: Femur length (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur polar moment of inertia (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical envelop total volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical envelop mineralized volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical envelop porosity (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [%]',\n",
       " 'Pharmacology, toxicology: Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) maximum after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl]',\n",
       " 'Pharmacology, toxicology: Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 1 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical thickness (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm]',\n",
       " 'Central nervous system, peripheral nervous system, skin, behavior: Somatosensory response, mechanical sensitivity using Von Frey test, threshold for males and females [force in mg]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical material bone mineral density (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cross-sectional volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical marrow volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur moment of inertia around the shorter axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for males [cm]',\n",
       " 'Musculoskeletal system, morphology: Femur moment of inertia around the longer axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular total volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular mineralized bone volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular seperation (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular thickness (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular number (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [1/mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone structural model index (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone connectivity density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [1/mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone volume fraction (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Femur polar moment of inertia (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Infectious disease, immune system: Ectromelia virus mortality score (combined data from Brownstein 1999 and Rice et al. 2010) [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale]',\n",
       " 'Musculoskeletal system, morphology: Femur material bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) (BXD13 winsorized from 963 to 1016) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur mineralized volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) (BXD13 winsorized from 10.375 to 11.5)[mm3]',\n",
       " \"Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, Hargreaves' test for males and females\",\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, hot plate test, average of two trials for males and females [sec]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for males [cm]',\n",
       " 'Central nervous system, behavior: Motor coordination effect of saline control injection (ip), difference in time on rotarod between training session and saline for males [sec]',\n",
       " 'Central nervous system, behavior: Motor coordination, rotarod performance, untreated training trial for males [sec]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical marrow volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cross-sectional volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical material bone mineral density (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical thickness (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical envelop porosity (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [%]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical envelop mineralized volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur cortical envelop total volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (BXD78 winsorised from 1158 to 1105) (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur mineralized volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur length (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Pharmacology, toxicology: Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 2 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl]',\n",
       " 'Pharmacology, toxicology: Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 3 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl]',\n",
       " 'Pharmacology, toxicology: Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 7 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone degree of anisotropy (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular material bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular apparent bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, tail withdrawal latency for males and females [sec]',\n",
       " 'Musculoskeletal system, morphology: Femur moment of inertia around the shorter axis (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, mechanical nociception, tail clip latency for males and females [sec]',\n",
       " 'Musculoskeletal system, morphology: Femur moment of inertia around the longer axis (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Femur gracility index (length /volume, age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm2]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males [%]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males [cm]',\n",
       " 'Central nervous system, adult neurogenesis: Newly generated BrdU-labeled cells in the rostral migratory stream of adult mouse brain, data corrected for age, sex, body weight, and strain epoch effects [N cells per mm of RMS length]',\n",
       " 'Central nervous system, adult neurogenesis: Proliferation of BrdU-labeled cells in subgranular zone, 1h BrdU injection, data corrected for age effects [n cells]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in open arms of a plus maze for males [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in middle of an elevated plus maze for males [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males [n]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, entries into open arms of a plus maze for males [n]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for males [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in closed arms of an elevated plus maze for males [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males [cm]',\n",
       " 'Central nervous system, adult neurogenesis: Newly generated BrdU-labeled cells in the rostral migratory stream of adult mouse brain, data corrected for age effects [N cells per mm of RMS length]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males [sec]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip) for cocaine, locomotion from 15-20 min after injection for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for males [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males and females [sec]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males [mg/dl XX min after injection]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males [cm]',\n",
       " 'Central nervous system, pharmacology, behavior: Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, percentage of locomotion in light side of a light-dark box for males and females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in light side of a light-dark box for males and females [sec]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone structural model index (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Central nervous system, behavior: Anxiety assay, percentage time in light side of a light-dark box for males and females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, transitions between light and dark sides of a light-dark box for males and females [n]',\n",
       " 'Central nervous system, behavior: Anxiety assay, locomotion in the light compartment of a light-dark box for males and females [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in dark side of a light-dark box for males and females [sec]',\n",
       " 'Central nervous system, behavior: Open field behavior, percentage of distance in the center for males and females [%]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular seperation (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Central nervous system, behavior: Zero maze, latency to enter an open quadrant for males [sec]',\n",
       " 'Central nervous system, behavior: Locomotion in zero maze for males [n beam breaks]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular thickness (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular number (age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular total volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone connectivity density (age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone volume fraction (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular mineralized bone volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, contextual activity for males [units]',\n",
       " 'Central nervous system, behavior, learning and memory: Fear conditioning response, cue conditioning, activity suppression after third tone-shock pairing for males [units]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity after third tone-shock pairing for males [n beam breaks/30 sec test] ',\n",
       " 'Central nervous system, behavior: Open field behavior, percentage of time in center for males and females [%]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity after first tone shock pairing for males [n beam breaks/30 sec test]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity during third tone-shock pairing for males [units]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity during second tone-shock pairing for males [units]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity during first tone-shock pairing for males [units]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity in altered context during presentation of cue for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity after second tone-shock pairing for males [n beam breaks/30 sec test]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 0-5 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Open field behavior, time in corners for males and females [min]',\n",
       " 'Central nervous system, behavior: Open field behavior, locomotion from 0-5 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Open field behavior, percentage of distance in the perimeter for males and females [%]',\n",
       " 'Central nervous system, behavior: Open field behavior, percentage of time in perimeter for males and females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, entries in closed quadrants of a zero maze for males and females [n]',\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, hot plate latency for males and females [sec]',\n",
       " 'Central nervous system, behavior: Locomotion in dark compartment of a light-dark box for males and females [cm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular apparent bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Central nervous system, behavior: Anxiety assay, entries into open quadrants of a zero maze for males and females [n]',\n",
       " 'Central nervous system, behavior: Anxiety assay, latency to enter an open quadrant of a zero maze for males and females [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, percentage time in open quadrants of a zero maze for males and females [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in closed quadrants of a zero maze for males and females [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in open quadrants of a zero maze for males and females [sec]',\n",
       " 'Central nervous systems, behavior: Effects of chronic variable stress (unstressed control) freezing to context after fear conditioning (measured for 10 minutes) in singly-housed 3-4 month-old males (Figure 2B left)[sec]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone degree of anisotropy (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Tibia length (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Central nervous system, behavior: Open field behavior, locomotion for entire test period for males and females [cm]',\n",
       " 'Central nervous system, behavior: Motor coordination, rotarod performance, untreated training trial for females [sec]',\n",
       " 'Central nervous system, behavior: Saline control response (dose ip), motor coordination effects, difference in time on rotarod between training session and saline for females [sec]',\n",
       " 'Central nervous system, behavior: Fear conditioning response, activity in altered context for males [units]',\n",
       " 'Central nervous system, behavior: Open field behavior, locomotion from 10-15 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Open field behavior, locomotion from 15-20 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Open field behavior, locomotion from 5-10 min for males and females [cm]',\n",
       " 'Central nervous system, behavior: Open field activity, habituation ratio for males and females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 0-20 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 10-15 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for females [cm]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 15-20 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 5-10 min for males and females [n beam breaks]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for females [cm]',\n",
       " 'Central nervous system, behavior: Saline control response (10 ml/kg ip), locomotion from 15-20 min after injection for females [cm]',\n",
       " 'Central nervous system, behavior: Fear conditioning behavior, baseline activity in apparatus for males [units]',\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, tail withdrawal latency for males [sec]',\n",
       " 'Central nervous system, behavior: Locomotion in both compartments of a light-dark box for males [cm]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical marrow volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (BXD63 winsorized from 0.406 to 0.52; BXD 39 winsorized from 0.465 to 0.53; BXD1 winsorized from 1.157 to 1.04;B',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical envelop mineralized volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical envelop porosity (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [%]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical thickness (age-adjusted, females only) measured at midshaft by microcomputed tomography (BXD39 winsorized from 0.161 to 0.17) (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical material bone mineral density (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia cross-sectional volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (BXD63 winsorized from 0.734 to 0.86; BXD39 winsorized from 0.767 to 0.87; BXD48a winsorized from 1.54 to 1.40;',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia polar moment of inertia (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in dark side of a light-dark box for males [sec]',\n",
       " 'Musculoskeletal system, morphology: Tibia moment of inertia around the shorter axis (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Tibia moment of inertia around the longer axis (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical thickness (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical envelop porosity (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [%]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical envelop mineralized volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical envelop total volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical envelop total volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone degree of anisotropy (age-adjusted, females only) measured by microcomputed tomography (BXD66 winsorized from 1.319 to 1.345; BXD64 winsorized from 1.895 to 1.79) to (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular material bone mineral density (age-adjusted, females only) measured by microcomputed tomography (BXD78 winsorized from 787 to 806) (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular apparent bone mineral density (age-adjusted, females only) measured by microcomputed tomography (BXD12 winsorized from 33.601 to 46; BXD39 winsorized from 210.695 to 182; BXD64 winsorized from 251.126 t',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular seperation (age-adjusted, females only) measured by microcomputed tomography (BXD74 winsorized from 0.081 to 0.181) (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular thickness (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular number (age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone structural model index (age-adjusted, females only) measured by microcomputed tomography (uCT) [ratio]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone connectivity density (age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm3]',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular bone volume fraction (age-adjusted, females only) measured by microcomputed tomography (BXD12 winsorized from 0.035 to 0.08; BXD39 winsorized from 0.219 to 0.174; BXD64 winsorized from 0.260 to 0.175) (',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular mineralized bone volume (age-adjusted, females only) measured by microcomputed tomography (BXD12 winsorized from 0.035 to 0.08; BXD39 winsorized from 0.334 to 0.26; BXD64 winsorized from 0.386 to 0.26',\n",
       " 'Musculoskeletal system, morphology: Femur trabecular total volume (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia cortical material bone mineral density (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia cross-sectional volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3]',\n",
       " 'Musculoskeletal system, morphology: Tibia moment of inertia around the longer axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Tibia moment of inertia around the shorter axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Musculoskeletal system, morphology: Tibia polar moment of inertia (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2]',\n",
       " 'Infectious disease, immune system: Malaria susceptibility, murine Plasmodium yoelli 17X-lethal (PY17X-L) [0=100% resistant, 1= 100% susceptible]',\n",
       " 'Central nervous system, behavior: Anxiety assay, locomotion in the light compartment of a light-dark box for males [cm]',\n",
       " 'Central nervous system, behavior: Locomotion in dark compartment of a light-dark box for males [cm]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in closed quadrants of a zero maze for males [sec]',\n",
       " 'Central nervous system, behavior: Open field behavior, locomotion for entire test period for males [cm]',\n",
       " 'Central nervous system, behavior: Open field behavior, percentage of distance in the perimeter for males [%]',\n",
       " 'Central nervous system, behavior: Open field behavior, percentage of time in perimeter for males [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, entries in closed quadrants of a zero maze for males [n]',\n",
       " 'Central nervous system, behavior: Anxiety assay, entries in open quadrants of a zero maze for males [n]',\n",
       " 'Central nervous system, behavior: Anxiety assay, percentage of time in open quadrants of a zero maze for males [%]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in open quadrants of a zero maze for males [sec]',\n",
       " 'Central nervous system, behavior: Anxiety assay, time in light side of a light-dark box for males [sec]',\n",
       " 'Musculoskeletal system, morphology: Tibia material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3]',\n",
       " \"Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception using Hargreaves' test for males [units]\",\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, hot plate test, average of two trials for males [sec]',\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, mechanical nociception, tail clip latency for males [sec]',\n",
       " 'Central nervous system, peripheral nervous system, behavior: Somatosensory response, mechanical sensitivity using Von Frey test, threshold for males [Force in mg]',\n",
       " 'Central nervous system, peripheral nervous system, behavior, nociception: Pain response, thermal nociception, hot plate latency for males [sec]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 5-10 min for males [n beam breaks]',\n",
       " 'Central nervous system, behavior: Open field behavior, vertical activity (rears) from 15-20 min for males [n beam breaks]',\n",
       " ...]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(other_data[3][1].sort_values(\"Strains\", ascending=False)[16:][\"Phenotype\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
